KALVISTA PHARMACEUTICALS INC (KALV) Stock Overview
NASDAQ:KALV - US4834971032 - Common Stock
KALV Key Statistics, Chart & Performance
The current stock price of KALV is 14.29 USD. In the past month the price increased by 7.36%. In the past year, price increased by 15.8%.
KALV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.01 | 374.37B | ||
| AMGN | AMGEN INC | 13.16 | 154.47B | ||
| GILD | GILEAD SCIENCES INC | 14.56 | 139.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.67 | 102.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.59B | ||
| ARGX | ARGENX SE - ADR | 76.2 | 43.23B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.69 | 39.47B | ||
| INSM | INSMED INC | N/A | 30.71B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.19B | ||
| NTRA | NATERA INC | N/A | 23.24B | ||
| BIIB | BIOGEN INC | 8.72 | 20.47B |
Related stock screener links
About KALV
Company Profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The company is headquartered in Cambridge, Massachusetts and currently employs 270 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The firm is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
Company Info
KALVISTA PHARMACEUTICALS INC
55 Cambridge Pkwy Ste 901E
Cambridge MASSACHUSETTS 02142 US
CEO: T. Andrew Crockett
Employees: 150
Phone: 18579990075
KALVISTA PHARMACEUTICALS INC / KALV FAQ
What is the stock price of KALVISTA PHARMACEUTICALS INC today?
The current stock price of KALV is 14.29 USD. The price increased by 6.17% in the last trading session.
What is the ticker symbol for KALVISTA PHARMACEUTICALS INC stock?
The exchange symbol of KALVISTA PHARMACEUTICALS INC is KALV and it is listed on the Nasdaq exchange.
On which exchange is KALV stock listed?
KALV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KALVISTA PHARMACEUTICALS INC stock?
16 analysts have analysed KALV and the average price target is 32.3 USD. This implies a price increase of 126.03% is expected in the next year compared to the current price of 14.29. Check the KALVISTA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KALVISTA PHARMACEUTICALS INC worth?
KALVISTA PHARMACEUTICALS INC (KALV) has a market capitalization of 719.36M USD. This makes KALV a Small Cap stock.
How many employees does KALVISTA PHARMACEUTICALS INC have?
KALVISTA PHARMACEUTICALS INC (KALV) currently has 150 employees.
What are the support and resistance levels for KALVISTA PHARMACEUTICALS INC (KALV) stock?
KALVISTA PHARMACEUTICALS INC (KALV) has a support level at 13.03 and a resistance level at 15.4. Check the full technical report for a detailed analysis of KALV support and resistance levels.
Should I buy KALVISTA PHARMACEUTICALS INC (KALV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KALV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KALV, evaluating the profitability, health, valuation and growth aspects
- KALVISTA PHARMACEUTICALS INC (KALV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KALVISTA PHARMACEUTICALS INC (KALV) Sales and EPS estimates to see what analysts future expectations are.
- KALVISTA PHARMACEUTICALS INC (KALV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KALVISTA PHARMACEUTICALS INC (KALV) Insider and Institutional Ownership to learn about the owners and their transactions.
- KALVISTA PHARMACEUTICALS INC (KALV) Stock Chart to make your own analysis
- KALVISTA PHARMACEUTICALS INC (KALV) Latest news and press-releases to stay up to date.
Does KALVISTA PHARMACEUTICALS INC (KALV) stock pay dividends?
KALV does not pay a dividend.
When does KALVISTA PHARMACEUTICALS INC (KALV) report earnings?
KALVISTA PHARMACEUTICALS INC (KALV) will report earnings on 2025-09-04.
What is the Price/Earnings (PE) ratio of KALVISTA PHARMACEUTICALS INC (KALV)?
KALVISTA PHARMACEUTICALS INC (KALV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.55).
What is the Short Interest ratio of KALVISTA PHARMACEUTICALS INC (KALV) stock?
The outstanding short interest for KALVISTA PHARMACEUTICALS INC (KALV) is 22.44% of its float. Check the ownership tab for more information on the KALV short interest.
KALV Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KALV. When comparing the yearly performance of all stocks, KALV turns out to be only a medium performer in the overall market: it outperformed 57.23% of all stocks.
KALV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KALV. KALV has a great financial health rating, but its profitability evaluates not so good.
KALV Financial Highlights
Over the last trailing twelve months KALV reported a non-GAAP Earnings per Share(EPS) of -3.55. The EPS decreased by -4.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.24% | ||
| ROE | -116.71% | ||
| Debt/Equity | 0 |
KALV Forecast & Estimates
16 analysts have analysed KALV and the average price target is 32.3 USD. This implies a price increase of 126.03% is expected in the next year compared to the current price of 14.29.